Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01026493 : Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A

- Histologically confirmed diagnosis of 1 of the following:

- Any intracranial high-grade glioma (phase I*)

- Glioblastoma or gliosarcoma (phase II*)

- Patients whose original histology was low-grade glioma are eligible provided they
were subsequently diagnosed with glioblastoma or gliosarcoma

- Unequivocal radiographic evidence for tumor progression by MRI within 14 days prior
to registration and with a stable or decreasing dose of steroids at least 5 days
prior to scanning OR recent resection (registration within 30 days of resection) as
long as all of the following conditions are met:

- Patients must have recovered from the effects of surgery

- Residual disease following resection of recurrent glioblastoma is not mandated
for eligibility into the study; to best assess the extent of residual disease
post-operatively, a post-operative MRI scan should be performed within 28 days
prior to registration and within 96 hours post surgery (although 24 hours would
be optimum)

- Prior radiation is required for the phase I* arm

- Patients must have completed a course of radiation therapy and at least 2
consecutive adjuvant cycles of temozolomide (phase II*)

- A stable or decreasing dose of steroids at least 5 days prior to scanning is not
mandated for patients who had a recent resection

- No evidence of acute (i.e., new and active) intratumoral hemorrhage on MRI

- Patients with MRI demonstrating old hemorrhage or subacute blood after a
neurosurgical procedure (biopsy or resection) are eligible NOTE: *Phase I was
closed and phase II was opened on 3/6/12.


- Karnofsky performance status 70-100%

- WBC ? 3,000/mm^3

- ANC ? 1,500/mm^3

- Platelet count ? 100,000/mm^3

- Hemoglobin ? 10.0 g/dL (transfusion or other intervention allowed)

- SGOT ? 3.0 times upper limit of normal (ULN)

- SGPT ? 3.0 times ULN

- Bilirubin ? 1.25 times ULN

- Creatinine < 1.7 mg/dL OR estimated GFR ? 30 mL/min

- Urine protein:creatinine ratio ? 0.5 OR urine protein < 1,000 mg by 24-hour urine

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for ? 6 months after
completion of study therapy

- Able to undergo brain MRI scans with IV gadolinium

- Able to swallow oral medications

- Patients with a history of seizure, or new onset of seizures, should be clinically
controlled with no seizures for at least 14 days prior to registration

- No other prior invasive malignancy (except for nonmelanomatous skin cancer or
carcinoma in situ of the cervix) unless the patient has been disease-free and off
therapy for that disease for ? 3 years

- No severe, active comorbidity, including any of the following:

- Transmural myocardial infarction or unstable angina within the past 6 months

- Evidence of recent myocardial infarction or ischemia as indicated by S-T
elevations of ? 2 mm on EKG performed within the past 14 days

- NYHA class II-IV congestive heart failure requiring hospitalization within the
past 12 months

- Stroke or transient ischemic attack within the past 6 months

- Cerebral vascular accident within the past 6 months

- Serious and inadequately controlled cardiac arrhythmia

- Clinically significant peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Serious non-healing would, ulcer, or bone fracture

- Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess
within the past 28 days

- Significant traumatic injury within the past 28 days

- Acute bacterial or fungal infection requiring IV antibiotics at the time of
study registration

- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy within the past 14 days

- AIDS based upon current CDC definition (HIV testing is not required)

- No condition that would impair the ability to swallow pills (e.g., GI tract disease
resulting in an inability to take oral medication or a requirement for IV
alimentation, prior surgical procedures affecting absorption, or active peptic ulcer

- No disease that would obscure toxicity or dangerously alter drug metabolism

- Not on dialysis

- No history of chronic hepatitis B or C NOTE: **Required for patients who received
prior bevacizumab and developed known clinically significant nephrotic syndrome
during treatment and whose baseline values have not returned to normal.


- See Disease Characteristics

- Recovered from the toxic effects of prior therapy

- Prior interstitial brachytherapy, Gliadel wafer, or stereotactic radiosurgery allowed
provided there is confirmation of progressive disease by PET scan, thallium scan, MRI
spectroscopy, perfusion MRI, or surgical documentation

- No more than 3 prior treatment regimens (phase I*)

- No more than 2 prior treatment regimens for recurrent glioblastoma/gliosarcoma (phase

- More than 28 days since prior major surgical procedure or open biopsy (with the
exception of craniotomy)

- At least 28 days since prior investigational agents or cytotoxic agents (42 days for
nitrosoureas, 21 days for procarbazine, and 14 days for vincristine)

- At least 14 days since prior non-cytotoxic agents (e.g., bevacizumab, interferon,
tamoxifen, thalidomide, isotretinoin, or tyrosine kinase inhibitors)

- No concurrent highly-active antiretroviral therapy

- No concurrent herbal products of unknown constitution

- No concurrent major surgical procedures NOTE: *Phase I was closed and phase II was
opened on 3/6/12.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557